190 related articles for article (PubMed ID: 27249744)
21. The presence of a bulky mediastinal mass of 7 cm or greater in diameter confers an adverse prognosis to patients with advanced Hodgkin lymphoma in case of negative interim PET/CT.
Lopez-Alonso R; Qi S; Mashiach T; Weiler-Sagie M; Yahalom J; Dann EJ
Leuk Lymphoma; 2021 Jun; 62(6):1313-1324. PubMed ID: 33478289
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
[TBL] [Abstract][Full Text] [Related]
23. Predictive value on advance hodgkin lymphoma treatment outcome of end-of treatment FDG PET/CT in the HD0607 clinical trial.
Biggi A; Chauvie S; Fallanca F; Guerra L; Bergesio F; Menga M; Bianchi A; Gregianin M; Chiaravalloti A; Schillaci O; Pavoni C; Patti C; Picardi M; Romano A; Schiavotto C; Sorasio R; Viviani S; La Nasa G; Trentin L; Rambaldi A; Gallamini A
Hematol Oncol; 2023 Aug; 41(3):415-423. PubMed ID: 36534947
[TBL] [Abstract][Full Text] [Related]
24. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses.
Gallamini A; Patti C; Viviani S; Rossi A; Fiore F; Di Raimondo F; Cantonetti M; Stelitano C; Feldman T; Gavarotti P; Sorasio R; Mulè A; Leone M; Rambaldi A; Biggi A; Barrington S; Fallanca F; Ficola U; Chauvie S; Gianni AM;
Br J Haematol; 2011 Mar; 152(5):551-60. PubMed ID: 21166786
[TBL] [Abstract][Full Text] [Related]
25. [Treatment strategy for newly diagnosed classical Hodgkin lymphoma: current achievements using interim PET-guided therapy].
Kusumoto S
Rinsho Ketsueki; 2020; 61(9):1244-1251. PubMed ID: 33162522
[TBL] [Abstract][Full Text] [Related]
26. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
27. PET-adapted therapy for advanced Hodgkin lymphoma - systematic review.
Amitai I; Gurion R; Vidal L; Dann EJ; Raanani P; Gafter-Gvili A
Acta Oncol; 2018 Jun; 57(6):765-772. PubMed ID: 29345517
[TBL] [Abstract][Full Text] [Related]
28. Role of [18F]-FDG-PET/MDCT in evaluating early response in patients with Hodgkin's lymphoma.
Orlacchio A; Schillaci O; Gaspari E; Della Gatta F; Danieli R; Bolacchi F; Ragano Caracciolo C; Mancini A; Simonetti G
Radiol Med; 2012 Oct; 117(7):1250-63. PubMed ID: 22327919
[TBL] [Abstract][Full Text] [Related]
29. Response assessment by positron emission tomography-computed tomography as compared with contrast-enhanced computed tomography in childhood Hodgkin lymphoma can reduce the need for radiotherapy in low- and middle-income countries.
Kalra M; Bakhshi S; Singh M; Seth R; Verma N; Jain S; Radhakrishnan V; Mandal P; Mahajan A; Arora RS; Dinand V; Kapoor G; Sajid M; Kumar R; Taluja A; Mallick S; Chandra J
Pediatr Blood Cancer; 2023 Feb; 70(2):e30091. PubMed ID: 36411263
[TBL] [Abstract][Full Text] [Related]
30. Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients.
Zinzani PL; Rigacci L; Stefoni V; Broccoli A; Puccini B; Castagnoli A; Vaggelli L; Zanoni L; Argnani L; Baccarani M; Fanti S
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):4-12. PubMed ID: 21894546
[TBL] [Abstract][Full Text] [Related]
31. Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.
Gandikota N; Hartridge-Lambert S; Migliacci JC; Yahalom J; Portlock CS; Schöder H
Cancer; 2015 Jun; 121(12):1985-92. PubMed ID: 25739719
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic recommendations for early stage Hodgkin lymphomas.
Depaus J; Delcourt A; André M
Br J Haematol; 2019 Jan; 184(1):9-16. PubMed ID: 30485401
[TBL] [Abstract][Full Text] [Related]
33. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
34. Revisiting the predictive role of 18F-fluorodeoxyglucose positron emission tomography/computerized tomography on treatment outcome in early-stage favorable Hodgkin lymphoma.
Gallamini A; Sudria A; Kurlapski M; Gastaud L
Hematol Oncol; 2023 Oct; 41(4):608-611. PubMed ID: 37805963
[TBL] [Abstract][Full Text] [Related]
35. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.
Mesguich C; Cazeau AL; Bouabdallah K; Soubeyran P; Guyot M; Milpied N; Bordenave L; Hindié E
Br J Haematol; 2016 Nov; 175(4):652-660. PubMed ID: 27539369
[TBL] [Abstract][Full Text] [Related]
36. Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's Lymphoma.
Al-Ibraheem A; Anwer F; Juweid ME; Shagera QA; Khalaf AN; Obeidat S; Mansour A; Ma'koseh M; Halahleh K; Jaradat I; Almasri N; Mansour A
Sci Rep; 2022 Oct; 12(1):17702. PubMed ID: 36271128
[TBL] [Abstract][Full Text] [Related]
37. PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.
Barrington SF; Kirkwood AA; Franceschetto A; Fulham MJ; Roberts TH; Almquist H; Brun E; Hjorthaug K; Viney ZN; Pike LC; Federico M; Luminari S; Radford J; Trotman J; Fosså A; Berkahn L; Molin D; D'Amore F; Sinclair DA; Smith P; O'Doherty MJ; Stevens L; Johnson PW
Blood; 2016 Mar; 127(12):1531-8. PubMed ID: 26747247
[TBL] [Abstract][Full Text] [Related]
38. Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.
Torok JA; Wu Y; Prosnitz LR; Kim GJ; Beaven AW; Diehl LF; Kelsey CR
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):54-9. PubMed ID: 25863754
[TBL] [Abstract][Full Text] [Related]
39. Risk- and response-adapted strategies for the management of Hodgkin lymphoma.
Remer M; Johnson PW
Chin Clin Oncol; 2015 Mar; 4(1):13. PubMed ID: 25841720
[TBL] [Abstract][Full Text] [Related]
40. [Our experience with the treatment of Hodgkin lymphoma patients].
Illés Á; Garai I; Miltényi Z
Orv Hetil; 2023 Mar; 164(11):403-410. PubMed ID: 36934353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
